The predictive role of plasma mutant allele fraction to antiangiogenic drugs in patients with mCRC: An expanded analysis of surrogate biomarkers of response to first-line treatment with bevacizumab.

Giulia Martini,Elena Elez,Francesco M. Mancuso,María Auxiliadora Gómez,Ginevra Caratu,Judit Matito,Guillem Argiles,Nuria Mulet,Iosune Baraibar,Javier Ros,Ariadna Garcia,Raquel Comas,Marta Ligero,Cristina Santos,Paolo Nuciforo,Rodrigo Dienstmann,Josep Tabernero,Enrique Aranda,Raquel Perez-Lopez,Ana Vivancos

The predictive role of plasma mutant allele fraction to antiangiogenic drugs in patients with mCRC: An expanded analysis of surrogate biomarkers of response to first-line treatment with bevacizumab.

2020

3541Background: So far, no biomarkers of response to anti-angiogenic drugs are available in colorectal cancer (CRC) treatment. Liquid biopsy tracks dynamic mutational changes in CRC patients (pts)....

Keywords:

Bevacizumab
Oncology
in patient
Biomarker (medicine)
first line treatment
Internal medicine
Pathology
Medicine
mutant allele

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations